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NOVELTY AND IMPACT 
This is the first study to present evidence of statistical interactions between postmenopausal 
estrogen-alone therapy use and confirmed ovarian cancer susceptibility alleles on risk of serous 
and endometrioid ovarian cancer, suggesting effects that may not be independent. Of particular 
interest is the interaction with rs10069690, a functional variant located in TERT, a gene involved 
in the formation of the enzyme telomerase and whose expression is upregulated by estrogen. 
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ABSTRACT 
Menopausal estrogen-alone therapy (ET) is a well-established risk factor for serous and 
endometrioid ovarian cancer. Genetics also plays a role in ovarian cancer, which is partly 
attributable to 18 confirmed ovarian cancer susceptibility loci identified by genome-wide 
association studies. The interplay among these loci, ET use, and ovarian cancer risk has yet to be 
evaluated. We analyzed data from 1,414 serous cases, 337 endometrioid cases, and 4,051 
controls across 10 case-control studies participating in the Ovarian Cancer Association 
Consortium (OCAC). Conditional logistic regression was used to determine the association 
between the confirmed susceptibility variants and risk of serous and endometrioid ovarian cancer 
among ET users and non-users separately and to test for statistical interaction. A splicing variant 
in TERT, rs10069690, showed a statistically significant interaction with ET use for risk of serous 
ovarian cancer (pint=0.013). ET users carrying the T allele had a 51% increased risk of disease 
(OR=1.51, 95% CI 1.19-1.91), which was stronger for long-term ET users of 10+ years 
(OR=1.85, 95% CI 1.28-2.66, pint=0.034).  Non-users showed essentially no association 
(OR=1.08, 95% CI 0.96-1.21). Two additional genomic regions harboring rs7207826 (C allele) 
and rs56318008 (T allele) also had significant interactions with ET use for the endometrioid 
histotype (pint=0.021 and pint=0.037, respectively). Hence, three confirmed susceptibility variants 
were identified whose associations with ovarian cancer risk are modified by ET exposure; 
follow-up is warranted given that these interactions are not adjusted for multiple comparisons. 
These findings, if validated, may elucidate the mechanism of action of these loci.
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INTRODUCTION 
The etiology of ovarian carcinoma (ovarian cancer) is influenced by several hormonal 
factors, including menopausal hormone therapy (HT) use. Approximately five million women in 
the United States currently use HT, and according to the National Health and Nutrition 
Examination Survey (NHANES) in 2010, the most commonly used type of HT among women 
aged 40 years and older is estrogen-alone therapy (ET) (1,2).  ET is a well-established risk factor 
for serous and endometrioid ovarian cancer (2-4).  Most recently, Lee et al demonstrated that use 
of ET postmenopausally was associated with a 57% and 82% increased risk of serous and 
endometrioid ovarian cancer, respectively (5); the meta-analysis by the Collaborative Group on 
Epidemiological Studies of Ovarian Cancer showed these histotype effects as well (2).   
Ovarian cancer also has a strong genetic component. A large part is attributable to high-
penetrance susceptibility mutations, but common variants identified using genome-wide 
association studies (GWASs) play important roles as well. There are currently 18 confirmed 
ovarian cancer common susceptibility loci that explain approximately 3.9% of the disease’s 
excess familial risk (6-13). Each of these common variants is associated with extremely modest 
relative risk estimates, but it is possible that interactions between non-genetic and genetic risk 
factors exist, thereby putting some women at higher risk. 
Pearce et al previously examined the interactive effects between six GWAS-identified 
common variants and five well-accepted non-genetic risk factors: first-degree family history of 
ovarian cancer, tubal ligation, parity, oral contraceptive (OC) use, and personal history of 
endometriosis (14). However, menopausal ET, which has consistently been shown to be 
associated with risk of serous and endometrioid ovarian cancer (2,5), was not included in these 
analyses. Using data from the Ovarian Cancer Association Consortium (OCAC), we have 
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evaluated potential statistical interactions between menopausal ET use and the 18 confirmed 
ovarian cancer common susceptibility alleles. To our knowledge, this is the first study to 
investigate the interactions between menopausal ET use and ovarian cancer susceptibility loci on 
disease risk. 
 
MATERIALS AND METHODS 
 All studies included in this analysis had approval from ethics committees and written 
informed consent was obtained from all study participants. 
 
Study Populations 
A total of 10 case-control studies participating in the OCAC 
(http://apps.ccge.medschl.cam.ac.uk/consortia/ocac/index.html) were included in this analysis, 
with seven in the United States and three in Europe. Specific details for each of these studies 
have been published elsewhere (15-25), but their main study characteristics are presented in 
Table 1.  
We had a total of 5,403 serous and endometrioid cases and 13,337 controls across the 10 
OCAC studies; only serous and endometrioid cases were included as most studies have shown 
that only these histotypes are significantly associated with ET use (2,5,26).  However, only a 
proportion of these women had genetic data available, leaving us with 3,855 cases and 9,593 
controls. Further exclusions included the following: women who were less than 50 years of age 
at reference date, which was typically the date of diagnosis for cases and the date of interview for 
controls, (871 cases and 2,532 controls), had past diagnoses of cancer (other than non-melanoma 
skin cancer) (398 cases and 887 controls), had unknown or missing HT information (171 cases 
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and 365 controls), or had used HT in a combined estrogen-progestin form (664 cases and 1,758 
controls). Hence, our final dataset included 1,414 serous cases, 337 endometrioid cases, and 
4,051 controls. 
 
Genotype Data  
To date, 18 confirmed, genome-wide significant ovarian cancer susceptibility loci (p≤5.0 
x 10-8) have been identified (6-13).  However, subsequent fine mapping efforts have shown that 
in some instances, the originally published best “hit” in the confirmed region was no longer the 
most strongly associated single nucleotide polymorphism (SNP). Table 2 presents the originally 
published SNPs and, where applicable, the current best hits, which we used in the analysis 
presented here (6). 
Details regarding the genetic data have been previously described (9).  Briefly, existing 
genotype data from three GWASs, their replication efforts, and two large-scale arrays (the 
Collaborative Oncological Gene-Environment Study (iCOGS) and the Exome chip) were 
combined with data from the April 2012 release of the 1000 Genomes Project and imputation 
using the program IMPUTE2 (27) was carried out for all OCAC participants. Subjects from two 
studies, NCO and NEC, were split into two analytic sets based on the varying scope of genotype 
data (genome-wide versus array) available for imputation. This resulted in a total of 12 analytic 
sets for analysis (see Table 1 footnote). 
 
Exposure and Covariate Data 
Self-completed questionnaires and phone or in-person interviews were used to collect 
information on HT use and other potential confounding variables including age, OC use, parity, 
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hysterectomy, tubal ligation, endometriosis, and education. Given that use of ET increases risk of 
endometrial cancer in women with intact uteri (28), the majority of ET users were 
hysterectomized and hence, their true age at menopause was unknown. We therefore assumed 
that all women in our analysis had an age at menopause of 50, which is the average age at 
menopause for women in the Western world (29).  
Given the importance of menopause to ovarian cancer etiology, the effects of ET use 
prior to menopause when endogenous estrogen levels are naturally high could be inherently 
different from its effects after menopause (30). Therefore, we only considered women as ET 
users if they used ET after age 50 for at least one year. Non-users were women who had never 
used ET after age 50 (including women who only used ET before age 50) or had only used ET 
after age 50 for less than one year as the effect of such short-term use is likely to be minimal. 
However, a sensitivity analysis was conducted using a true “never” user baseline group, and the 
results did not change.  Duration of postmenopausal ET use was assessed in the following 
categories: 1 to <5 years, 5 to <10 years, and 10+ years. 
 
Statistical Analysis 
All models were conditioned on analytic set, five-year age category (50-54, 55-59, 60-64, 
65-69, 70-74, and 75+ years), and genetic ancestry (European, Asian, African, and other) as 
determined by the program LAMP (Local Ancestry in Admixed Populations) (31). Women with 
>90% European ancestry were classified as European, >80% Asian or African ancestry were 
classified as Asian or African, respectively, and those with mixed ancestry were classified as 
other (9). In addition, all models were adjusted for OC use (never [including <1 year of use], 1 to 
<2 years, 2 to <5 years, 5 to <10 years, and 10+ years), parity (never, 1 birth, 2+ births), 
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hysterectomy (yes/no), endometriosis (yes/no), tubal ligation (yes/no), and education (less than 
high school, high school, some college, college graduate or higher) since they were judged to be 
potentially important confounders a priori. Missing categories were created for women missing 
any of the covariates so their data could be included in the analysis. Data on hysterectomy status 
was not available from all sites, but sensitivity analyses showed that hysterectomy status did not 
substantially impact the estimates for ET or any of the SNPs. 
Weighted genetic risk scores, which took into account the 18 confirmed SNPs 
simultaneously, were calculated by taking the beta coefficients for each SNP’s association with 
risk of serous and endometrioid ovarian cancer using all OCAC studies in which genotype data 
was available (43 OCAC studies, which included 18,174 cases and 26,134 controls (9)) and 
multiplying them by the genotype value (0-2) for each subject (i.e., beta coefficients were 
derived from a much larger dataset). These values for the 18 SNPs were then summed to obtain 
each individual’s total risk score, which was then categorized into quartiles according to the 
distribution in controls for ease of interpretation. 
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for the main effect 
association between each SNP or genetic risk score quartile and disease risk using conditional 
logistic regression. This was done for the serous and endometrioid histotypes separately. 
Previous analyses that evaluated ET’s main effect on risk of serous ovarian cancer showed no 
difference by grade so all serous cases were combined in our analysis (5). These genetic 
associations were further stratified by whether or not ET was used after age 50. Because these 
gene-environment interaction analyses were primarily focused on understanding disease 
etiology, we tested for statistical interaction (i.e., departure from a multiplicative model) between 
the 18 ovarian cancer susceptibility loci or genetic risk score and ET use on risk of serous and 
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endometrioid ovarian cancer using the likelihood ratio test (LRT) comparing models with and 
without interaction terms (32). A similar approach was used to analyze the effect of duration 
categories of ET use for the associations showing a significant interaction with ever/never ET 
use. For completeness, we also assessed interactions on the additive scale by calculating 
interaction contrast ratios (ICRs) and 95% CIs for the ICRs; ICR values greater than zero with 
95% CIs that excluded zero indicated greater than additive effects. 
All p-values reported were two-sided and considered significant at p≤0.05. An adjusted 
p-value that factored in the number of tests for interaction conducted was considered as well. All 
analyses were performed using STATA release 14.0. 
 
RESULTS 
A total of 5,802 women were included in these analyses, with 1,414 serous cases, 337 
endometrioid cases, and 4,051 controls (Table 1). Approximately 13.6%, 20.0%, and 15.1% of 
the controls, serous cases, and endometrioid cases, respectively, reported using ET after age 50. 
In addition, 18 confirmed ovarian cancer SNPs were investigated here and their characteristics 
are presented in Table 2. For nine of the 18 SNPs, their corresponding previously reported best 
hits are listed as well (Table 2). 
Although the main effects of each of the 18 SNPs have been previously published, Table 
3 shows their main effects as well as the effects of genetic risk score in quartiles with serous 
ovarian cancer. There was a statistically significant interaction between ET use and the T allele 
of rs10069690 on chromosome 5 on risk of serous ovarian cancer that showed departure from 
both additivity and multiplicativity (ICR=0.55, 95% CI 0.16-0.94; pint for LRT=0.013) (Table 3). 
While the T allele of rs10069690 was associated with a 51% increased risk of serous ovarian 
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cancer among ET users (OR=1.51, 95% CI 1.19-1.91), there was essentially no risk among non-
users (OR=1.08, 95% CI 0.96-1.21). 
Table 4 presents the same information as Table 3, but for the endometrioid histotype. 
Two statistically significant interactions between the genetic variants rs7207826 and rs56318008 
and ET use on risk of disease that showed departure from multiplicativity were observed (pint for 
LRT=0.021 and pint for LRT=0.037, respectively) (Table 4). Rs7207826 (T allele) on 
chromosome 17 was positively associated with the endometrioid histotype among non-users of 
ET (OR=1.32, 95% CI 1.09-1.61), but showed a decreased risk of disease among ET users 
(OR=0.71, 95% CI 0.43-1.18). Similarly, non-users of ET carrying the C allele for rs56318008 
on chromosome 1 showed an increased risk of endometrioid ovarian cancer (OR=1.53, 95% CI 
1.21-1.92) whereas ET users showed a decreased risk (OR=0.82, 95% CI 0.46-1.45). Genetic 
risk score did not appear to interact with ET use on risk of either histotype (pint for LRT=0.52 for 
serous, pint for LRT=0.25 for endometrioid) (Tables 3 and 4). 
For each of the three SNPs that showed a statistically significant interaction with 
postmenopausal ET use on serous or endometrioid ovarian cancer risk at a p≤0.05 level on a 
multiplicative scale, the association between the SNP and risk of disease was assessed by 
duration of ET use. Rs7207826 and rs56318008 did not have significant interactions with 
duration for endometrioid ovarian cancer (pint for LRT=0.18 and pint for LRT=0.087, 
respectively). However, rs10069690 did have a significant interaction for serous ovarian cancer 
(pint for LRT=0.034); women who carried the T allele and had used ET for 10+ years had close 
to a two-fold increased risk relative to non-users of ET who carried the C (reference) allele 
(OR=1.85, 95% CI 1.28-2.66) (Table 5).  
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With 18 SNPs plus a genetic risk score for two histotypes and three additional duration 
interactions, we conducted a total of 41 tests for interaction in the analyses presented here. Four 
of these interactions were considered statistically significant at a p≤0.05 level. Although this is 
twice as many interaction associations as would be expected by chance at the p≤0.05 level, none 
of the them met a Bonferroni threshold for multiple comparisons of p=1.22 x 10-3 (0.05/41 tests). 
 
DISCUSSION 
 We have shown evidence of statistical interactions between postmenopausal ET use and 
three confirmed ovarian cancer susceptibility alleles with risk of serous and endometrioid 
ovarian cancer. Although none of the interactions we report here remained significant after 
adjusting for multiple comparisons, these results may still be relevant as they could contribute to 
our understanding of the mechanism of action for these loci.  
The most significant and biologically plausible interaction identified was rs10069690 for 
serous ovarian cancer, a SNP whose main effect has only been observed for the serous histotype 
(13). Rs10069690 is located in the TERT-CLPTM1L region of chromosome 5p15.33, a multi-
cancer susceptibility locus that encodes the reverse transcriptase subunit (hTERT) of telomerase, 
an enzyme known to help maintain telomere length and integrity. Telomere shortening is often 
associated with genetic instability and hence increased risk of cancer and death, but telomerase 
has been shown to counteract this process, making the expression of TERT important in 
preventing tumorigenesis. Evidence has suggested that sex steroid hormones, such as estrogen, 
may be good candidates as physiological regulators of TERT (33). Some findings have shown 
telomerase activity to be under hormonal control in estrogen-targeted tissues, including the 
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endometrium (34) and the ovary (35); the expression of TERT has been shown to be upregulated 
by estrogen (36,37).  
Recently, Killedar et al reported rs10069690 as a likely functional SNP since its risk-
associated T allele was shown to result in the co-production of full length-hTERT as well as an 
alternatively spliced transcript, which encodes a catalytically inactive protein that inhibits 
telomerase activity; this was thought to be due to a dominant negative effect of the protein since 
telomerase exists as a dimer and its catalytic activity requires both hTERT active sites to be 
functional (38). The decreased enzymatic activity may result in shorter telomeres, which could 
lead to an increased risk of genetic instability and subsequent carcinogenesis. Given the evidence 
suggesting estrogen’s role in the transcriptional regulation of hTERT, the elevated risk of serous 
ovarian cancer may be attributable to the inhibition of telomerase activity from higher levels of 
estrogen with prolonged ET use (OR=1.85, 95% CI 1.28-2.66 for 10+ years).  
Cancer cells have also been shown to activate telomerase to stabilize telomeres for 
continued proliferation and cellular immortalization. However, from this perspective, the 
inhibition of telomerase associated with rs10069690 would result in cell death of cancer cells and 
hence a decreased risk of disease particularly among ET users, which is contrary to our findings. 
Presently, it is unclear whether telomerase activation helps in the uncontrolled cellular 
proliferation of existing cancer cells or in the preservation of a non-malignant phenotype by 
maintaining the replicative longevity of ovarian cells (35). Our results appear to support the 
latter. 
 The additional two interactions observed with ET use were rs56318008 and rs7207826 
for endometrioid ovarian cancer. Rs56318008 is located near WNT4, a gene involved in 
steroidogenesis (39) and implicated in GWASs for risk of endometriosis (40), an estrogen-
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related gynecologic condition strongly associated with the endometrioid histotype (41). 
Rs7207826 is located near SKAP1, a gene that does not appear to be directly related to female 
sex hormones and is primarily involved in T cell signaling and the regulation of the lymphocyte 
function-associated antigen 1 gene (LFA-1).  It should be noted though that WNT4 and SKAP1 
have not been shown to be the targets of risk SNPs at these loci. 
 Although this study is the largest of its kind, it still has a modest sample size in which to 
attempt to discover interactions.  In addition, the self-reported nature of the exposure and 
covariate data used could be considered a limitation. However, studies have shown high 
agreement between information collected using interviews versus records for HT use (42) as well 
as other reproductive factors (43,44). Our results may be due to chance as these interactions do 
not survive correction for multiple hypothesis testing, but the fact that these are confirmed 
susceptibility alleles adds support to our findings. Given the role of estrogen in TERT activation 
and expression, rs10069690 is of particular interest. From a biological standpoint, this SNP 
appears to affect telomerase activity and hence, telomere maintenance, actions that could 
promote tumorigenesis if improperly regulated (38). Although we cannot rule out that the 
observed interaction may be due to a SNP in the region that is in linkage disequilibrium with 
rs10069690, the fact that rs10069690 is functional with biological plausibility supporting its 
interaction with ET use makes it a strong candidate. The other two SNPs implicated in this 
analysis are intriguing as well in that they are confirmed ovarian cancer susceptibility loci.  
However, as previously mentioned, the target genes for these SNPs are unknown and hence their 
relevance remains uncertain at this time.  
Our results highlight the complexity of ovarian cancer etiology. In addition, they provide 
evidence that the roles of ET and the 18 ovarian cancer common variants in ovarian 
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carcinogenesis may be beyond their independent effects. This is the first study, to our 
knowledge, to suggest potential gene-environment interactions in ovarian cancer in the context 
of HT use with confirmed susceptibility alleles. These findings, if replicated, may be critical for 
future risk prediction modeling. 
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Table 1. Description of studies included in analysis 
Study Name 
Study 
Abbrev. 
Country Study Period 
Method of Data 
Collection 
Number 
of 
Controls a 
Number of 
Serous 
Cases a 
Number of 
Endometrioid 
Cases a 
Disease of the Ovary and their 
Evaluation Study (23) 
DOV USA 2002-2009 In-person interview 547 (123) 218 (65) 53 (10) 
German Ovarian Cancer Study 
(15) 
GER Germany 1992-1998 
Self-completed 
questionnaire 
232 (39) 66 (11) 11 (4) 
Hawaii Ovarian Cancer Study 
(17) 
HAW USA 1994-2007 In-person interview 229 (28) 68 (13) 23 (6) 
Hormones and Ovarian Cancer 
Prediction (18) 
HOP USA 2003-2008 In-person interview 694 (68) 168 (28) 48 (7) 
Malignant Ovarian Cancer Study 
(24) 
MAL Denmark 1994-1999 
In-person or phone 
interview 
363 (47) 96 (11) 17 (2) 
North Carolina Ovarian Cancer 
Study b (19) 
NCO USA 1999-2008 In-person interview 401 (70) 189 (60) 47 (10) 
New England Case-Control Study 
of Ovarian Cancer b (21) 
NEC USA 1999-2008 In-person interview 394 (28) 211 (26) 56 (3) 
New Jersey Ovarian Cancer 
Study (25) 
NJO USA 2002-2008 Phone interview 112 (6) 63 (3) 20 (0) 
United Kingdom Ovarian Cancer 
Population Study (16) 
UKO 
United 
Kingdom 
2006-2007 In-person interview 490 (47) 27 (1) 9 (0) 
University of Southern California, 
Study of Lifestyle and Women’s 
Health (20,22) 
USC USA 1993-2008 In-person interview 589 (95) 308 (65) 53 (9) 
    Total: 
4,051 
(551) 
1,414 (283) 337 (51) 
a Number in parentheses indicates the number of postmenopausal ET users. 
b Subjects were split into two different analytic sets. 
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Table 2. Characteristics of the 18 SNPs included in the analysis and their previously reported best hits  
SNP 
Previously 
Published Best 
Hit a 
Chromosome 
Band 
Position 
Reference 
Allele(s) 
Tested 
Allele b 
Tested 
Allele 
Frequency c 
rs58722170 (6)  1p34.3 38096421 G C 0.15 
rs10069690 (13)  5p15.33 1279790 C T 0.35 
chr10:21878831:D rs1243180 (9) 10p12.31 21878831 CCCTTC - 0.14 
rs17329882 (6)  4q26 119949960 A C 0.15 
rs1879586 rs12942666 (12) 17q21.31 43567337 C G 0.08 
rs56318008 (6)  1p36 22470407 C T 0.20 
rs4808075 rs2363956 (7) 19p13.11 17390291 T C 0.16 
chr9:136138765:D (6)  9q34.2 136138765 CGCCCACCACTA - 0.13 
rs7207826 rs9303542 (9) 17q21.32 46500673 T C 0.31 
rs76837345 rs11782652 (9) 8q21.13 82668818 A G 0.04 
rs62274042 rs7651446 (9) 3q25.31 156435952 G A 0.01 
rs635634 (6)  9q34.2 136155000 C T 0.14 
rs3744763 (10)  17q12 36090885 G A 0.69 
chr17:29181220:I (6)  17q11.2 29181220 - T 0.13 
rs6755777 rs2072590 (8) 2q31.1 177043226 T G 0.82 
rs117224476 rs3814113 (11) 9q22.2 16907967 T G 0.16 
rs1400482 rs10088218 (8) 8q24.21 129541931 G A 0.09 
rs116133110 (6)  6q22.1 28480635 T C 0.46 
Note: chr10:21878831:D and chr17:29181220:I are listed as rs1449962376 and rs199661266, respectively, in 1000 Genomes. 
a If not specified, the previously published best hit is the same as the current best hit considered. 
b “-“ refers to a deletion. 
c Based on 1000 Genomes for all populations. For chr9:136138765:D (rs587729126), the tested allele frequency was based on the controls in the 
full OCAC dataset since the SNP is not listed in 1000 Genomes. 
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Table 3. Association between each of the 18 SNPs and genetic risk score and risk of serous ovarian cancer, stratified by ET use after age 50 
 Main Effect 
No ET Use 
(N=1,131 cases/3,500 
controls) 
ET Use 
(N=283 cases/551 controls) 
 
 ORa,b 95% CI ORa 95% CI ORa 95% CI 
p-value for 
interaction 
SNP        
     rs58722170 1.25 1.11 – 1.40 1.21 1.06 – 1.38 1.41 1.07 – 1.85 0.31 
     rs10069690 1.14 1.03 – 1.26 1.08 0.96 – 1.21 1.51 1.19 – 1.91 0.013 
     chr10:21878831:D 1.14 1.03 – 1.26 1.15 1.03 – 1.29 1.09 0.86 – 1.38 0.68 
     rs17329882 1.14 1.02 – 1.28 1.17 1.03 – 1.32 1.05 0.81 – 1.37 0.47 
     rs1879586 1.15 1.01 – 1.30 1.17 1.02 – 1.34 1.04 0.78 – 1.37 0.44 
     rs56318008 1.16 1.03 – 1.31 1.22 1.06 – 1.39 0.93 0.698 – 1.25 0.099 
     rs4808075 1.18 1.07 – 1.31 1.20 1.07 – 1.34 1.13 0.90 – 1.42 0.64 
     chr9:136138765:D 1.08 0.93 – 1.26 1.14 0.96 – 1.34 0.89 0.63 – 1.26 0.21 
     rs7207826 1.17 1.06 – 1.29 1.19 1.06 – 1.33 1.06 0.84 – 1.35 0.39 
     rs76837345 1.19 0.98 – 1.44 1.27 1.03 – 1.57 0.88 0.55 – 1.39 0.14 
     rs62274042 1.65 1.36 – 2.01 1.59 1.28 – 1.97 1.98 1.24 – 3.14 0.40 
     rs635634 1.14 1.01 – 1.29 1.16 1.01 – 1.33 1.06 0.80 – 1.40 0.56 
     rs3744763 0.89 0.81 – 0.97 0.89 0.80 – 0.98 0.88 0.72 – 1.09 0.97 
     chr17:29181220:I 0.89 0.80 – 0.99 0.88 0.78 – 0.99 0.93 0.72 – 1.19 0.71 
     rs6755777 0.98 0.89 – 1.09 0.98 0.88 – 1.10 0.99 0.80 – 1.24 0.94 
     rs117224476 0.73 0.64 – 0.84 0.76 0.65 – 0.88 0.62 0.45 – 0.85 0.26 
     rs1400482 0.80 0.69 – 0.92 0.81 0.69 – 0.95 0.77 0.54 – 1.09 0.79 
     rs116133110 0.86 0.78 – 0.95 0.87 0.78 – 0.97 0.83 0.66 – 1.04 0.69 
Risk score quartile        
     2nd vs. 1st quartile 1.15 0.94 – 1.41 1.18 0.95 – 1.48 0.98 0.61 – 1.59 
0.52      3rd vs. 1st quartile 1.56 1.29 – 1.90 1.53 1.24 – 1.90 1.77 1.12 – 2.81 
     4th vs. 1st quartile 2.26 1.87 – 2.72 2.31 1.88 – 2.85 2.00 1.30 – 3.08 
Note: OR=odds ratio, CI=confidence interval. P-values significant at a ≤0.05 level are indicated in bold. 
a Adjusted for OC use (never (including <1), 1 to <2, 2 to <5, 5 to <10, 10+ years), parity (0, 1, 2+ births), hysterectomy, endometriosis, tubal 
ligation, and education (less than high school, high school graduate, some college, college graduate or more); conditioned on age (50-54, 55-59, 
60-64, 65-69, 70-74, 75+), genetic ancestry (European, African, Asian, other), and analytic set. 
b All SNP main effects show genome-wide significance (p≤5.0 x 10-8) in the full OCAC dataset.
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Table 4. Association between each of the 18 SNPs and genetic risk score and risk of endometrioid ovarian cancer, stratified by ET use after age 50 
 Main Effect 
No ET Use 
(N=286 cases/3500 controls) 
ET Use 
(N=51 cases/551 controls) 
 
 ORa,b 95% CI ORa 95% CI ORa 95% CI 
p-value for 
interaction 
SNP        
     rs58722170 0.95 0.76 – 1.20 0.97 0.75 – 1.25 0.87 0.50 – 1.52 0.73 
     rs10069690 0.98 0.81 – 1.20 0.93 0.75 – 1.16 1.32 0.82 – 2.15 0.20 
     chr10:21878831:D 1.08 0.89 – 1.30 1.03 0.84 – 1.27 1.30 0.81 – 2.08 0.39 
     rs17329882 1.07 0.87 – 1.32 1.11 0.88 – 1.39 0.90 0.52 – 1.56 0.48 
     rs1879586 0.97 0.76 – 1.24 0.99 0.77 – 1.29 0.83 0.46 – 1.52                                           0.59
     rs56318008 1.40 1.13 – 1.74 1.53 1.21 – 1.92 0.82 0.46 – 1.45 0.037 
     rs4808075 1.01 0.83 – 1.22 1.02 0.83 – 1.25 0.97 0.60 – 1.56 0.84 
     chr9:136138765:D 0.99 0.74 – 1.31 1.03 0.76 – 1.41 0.74 0.35 – 1.55 0.41 
     rs7207826 1.21 1.01 – 1.45 1.32 1.09 – 1.61 0.71 0.43 – 1.18 0.021 
     rs76837345 1.25 0.89 – 1.75 1.14 0.78 – 1.68 1.69 0.83 – 3.46 0.35 
     rs62274042 1.12 0.75 – 1.68 1.10 0.70 – 1.70 1.34 0.47 – 3.75 0.73 
     rs635634 1.04 0.83 – 1.31 1.10 0.86 – 1.41 0.76 0.41 – 1.42 0.28 
     rs3744763 1.06 0.89 – 1.26 1.07 0.89 – 1.28 1.00 0.65 – 1.54 0.79 
     chr17:29181220:I 0.81 0.66 – 0.99 0.81 0.65 – 1.01 0.80 0.49 – 1.32 0.97 
     rs6755777 1.01 0.84 – 1.21 0.98 0.81 – 1.20 1.14 0.73 – 1.78 0.56 
     rs117224476 0.79 0.62 – 1.02 0.85 0.65 – 1.11 0.54 0.28 – 1.06 0.21 
     rs1400482 0.98 0.76 – 1.26 0.92 0.70 – 1.21 1.36 0.73 – 2.52 0.26 
     rs116133110 1.04 0.87 – 1.24 1.08 0.89 – 1.31 0.85 0.55 – 1.31 0.32 
Risk score quartile        
     2nd vs. 1st quartile 1.49 1.04 – 2.14 1.40 0.94 – 2.09 1.98 0.79 – 4.94 
0.25      3rd vs. 1st quartile 1.69 1.18 – 2.40 1.65 1.12 – 2.42 2.04 0.80 – 5.17 
     4th vs. 1st quartile 1.73 1.22 – 2.46 1.85 1.27 – 2.70 1.10 0.42 – 2.91 
Note: OR=odds ratio, CI=confidence interval. P-values significant at a ≤0.05 level are indicated in bold. 
a Adjusted for OC use (never (including <1), 1 to <2, 2 to <5, 5 to <10, 10+ years), parity (0, 1, 2+ births), hysterectomy, endometriosis, tubal 
ligation, and education (less than high school, high school graduate, some college, college graduate or more); conditioned on age (50-54, 55-59, 
60-64, 65-69, 70-74, 75+), genetic ancestry (European, African, Asian, other), and analytic set. 
b All SNP main effects show genome-wide significance (p≤5.0 x 10-8) in the full OCAC dataset. 
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Table 5. Association between rs10069690 and risk of serous ovarian cancer by duration of ET use after age 50 
SNP 
1 to <5 years 
(N=70 cases/193 controls) 
5 to <10 years 
(N=82 cases/168 controls) 
10+ years 
(N=131 cases/190 controls) 
 ORa 95% CI ORa 95% CI ORa 95% CI 
rs10069690 1.41 0.90 – 2.23 1.21 1.09 – 2.32 1.85 1.28 – 2.66 
       
p-value for interaction = 0.034 
Note: OR=odds ratio, CI=confidence interval. The reference group consists of women who did not use ET after age 50 and carried the C 
(reference) allele. 
a Adjusted for OC use (never (including <1), 1 to <2, 2 to <5, 5 to <10, 10+ years), parity (0, 1, 2+ births), hysterectomy, endometriosis, tubal 
ligation, and education (less than high school, high school graduate, some college, college graduate or more); conditioned on age (50-54, 55-59, 
60-64, 65-69, 70-74, 75+), genetic ancestry (European, African, Asian, other), and analytic set. 
